Skip to main content
. 2023 Oct 16;18:326. doi: 10.1186/s13023-023-02925-w

Fig. 10.

Fig. 10

The cost-effectiveness acceptability curves of patients with non-epithelioid histology. CE Cost-effectiveness, N Patients with non-epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin